Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses

Major progress in cancer immunotherapies have been obtained by the use of tumor targeting strategies, in particular with the development of bi-functional fusion proteins such as ImmTacs or BiTes, which engage effector T cells for targeted elimination of tumor cells. Given the significance of invaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lianjun, Donda, Alena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672503/
https://www.ncbi.nlm.nih.gov/pubmed/29163493
http://dx.doi.org/10.3389/fimmu.2017.01417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672503/
https://www.ncbi.nlm.nih.gov/pubmed/29163493
http://dx.doi.org/10.3389/fimmu.2017.01417

Ejemplares similares